-- CanSino Biologics (HKG:6185) received Chinese regulatory approval for its infant combination vaccine, according to a Hong Kong bourse filing Sunday.
Shares of the firm gained over 1% in morning trade Monday.
China's National Medical Products Administration approved the company's DTcP vaccine Tripecia, which protects from diphtheria, tetanus, and pertussis for infants below 2 years old.
CanSino said its vaccine is the first of its kind to be launched in China for infants.
Speciality Medicines (BOM:544738) has secured an order worth $1.5 million from an international company to distribute, market, and sell products, according to a BSE filing on Tuesday.The contract is expected to improve the company's distribution network and revenue visibility.The company's shares were up 5% in recent trade.
360 One Wam (NSE:360ONE, BOM:542772) has an average rating of buy and mean price target of 1,320.64 Indian rupees, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Jiangsu Hengli Hydraulic (SHA:601100) has an average rating of overweight and mean price target of 117.96 yuan, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)